A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 12 Weeks Treatment With 4 Doses of LIK066 Compared to Placebo in Japanese Patients With Obesity Disease
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2018
At a glance
- Drugs LIK 066 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 26 Sep 2018 Status changed to completed.
- 31 Aug 2018 Biomarkers information updated
- 13 Apr 2018 Planned End Date changed from 21 Sep 2018 to 23 Jul 2018.